Heart rate variability and Parkinson's disease severity.
Identifieur interne : 001081 ( PubMed/Corpus ); précédent : 001080; suivant : 001082Heart rate variability and Parkinson's disease severity.
Auteurs : D. Devos ; M. Kroumova ; R. Bordet ; H. Vodougnon ; J D Guieu ; C. Libersa ; A. DesteeSource :
- Journal of neural transmission (Vienna, Austria : 1996) [ 0300-9564 ] ; 2003.
English descriptors
- KwdEn :
- Autonomic Nervous System Diseases (diagnosis), Autonomic Nervous System Diseases (etiology), Autonomic Nervous System Diseases (physiopathology), Cardiovascular System (physiopathology), Chronobiology Disorders (diagnosis), Chronobiology Disorders (etiology), Chronobiology Disorders (physiopathology), Disease Progression, Female, Heart Rate (drug effects), Heart Rate (physiology), Humans, Hypokinesia (complications), Hypokinesia (drug therapy), Hypokinesia (physiopathology), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Surveys and Questionnaires, Sympathetic Nervous System (physiopathology), Up-Regulation (drug effects), Up-Regulation (physiology), Vagus Nerve (physiopathology).
- MESH :
- chemical , therapeutic use : Levodopa.
- complications : Hypokinesia, Parkinson Disease.
- diagnosis : Autonomic Nervous System Diseases, Chronobiology Disorders.
- drug effects : Heart Rate, Up-Regulation.
- drug therapy : Hypokinesia, Parkinson Disease.
- etiology : Autonomic Nervous System Diseases, Chronobiology Disorders.
- physiology : Heart Rate, Up-Regulation.
- physiopathology : Autonomic Nervous System Diseases, Cardiovascular System, Chronobiology Disorders, Hypokinesia, Parkinson Disease, Sympathetic Nervous System, Vagus Nerve.
- Disease Progression, Female, Humans, Male, Middle Aged, Surveys and Questionnaires.
Abstract
Heart rate variability (HRV) decrease in Parkinson's disease (PD) could only be a consequence of reduce motor activity besides of being a marker of cardiovascular dysautonomia. Under continuously recorded and standardised motor activity, we studied thirty patients compared to controls in 3 PD stages: group I: less than 2 year-evolution, slight impaired without L-dopa; group II: mildly impaired with L-dopa; group III: advanced PD with motor complications. No difference was observed between group I and controls. The diurnal low frequency power (LF) and the ratio of LF/high frequency (HF) power decreased in groups II and III. The nocturnal vagal indicators: HF power and pNN50 were decreased in group III. Those parameters were correlated with Off-drug-motor handicap, suggesting an evolutive HRV decrease with disease severity but not with On-drug-motor activity. The low LF despite the higher motor activity in group III, due to dyskinesias, suggested a defective cardiovascular up-regulation.
DOI: 10.1007/s00702-003-0016-8
PubMed: 12928836
Links to Exploration step
pubmed:12928836Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heart rate variability and Parkinson's disease severity.</title><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation><nlm:affiliation>Department of Neurology, EA 2683, CHU Lille, France. d-devos@chru-lille.fr</nlm:affiliation></affiliation></author><author><name sortKey="Kroumova, M" sort="Kroumova, M" uniqKey="Kroumova M" first="M" last="Kroumova">M. Kroumova</name></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name></author><author><name sortKey="Vodougnon, H" sort="Vodougnon, H" uniqKey="Vodougnon H" first="H" last="Vodougnon">H. Vodougnon</name></author><author><name sortKey="Guieu, J D" sort="Guieu, J D" uniqKey="Guieu J" first="J D" last="Guieu">J D Guieu</name></author><author><name sortKey="Libersa, C" sort="Libersa, C" uniqKey="Libersa C" first="C" last="Libersa">C. Libersa</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destee">A. Destee</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12928836</idno><idno type="pmid">12928836</idno><idno type="doi">10.1007/s00702-003-0016-8</idno><idno type="wicri:Area/PubMed/Corpus">001081</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001081</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Heart rate variability and Parkinson's disease severity.</title><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation><nlm:affiliation>Department of Neurology, EA 2683, CHU Lille, France. d-devos@chru-lille.fr</nlm:affiliation></affiliation></author><author><name sortKey="Kroumova, M" sort="Kroumova, M" uniqKey="Kroumova M" first="M" last="Kroumova">M. Kroumova</name></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name></author><author><name sortKey="Vodougnon, H" sort="Vodougnon, H" uniqKey="Vodougnon H" first="H" last="Vodougnon">H. Vodougnon</name></author><author><name sortKey="Guieu, J D" sort="Guieu, J D" uniqKey="Guieu J" first="J D" last="Guieu">J D Guieu</name></author><author><name sortKey="Libersa, C" sort="Libersa, C" uniqKey="Libersa C" first="C" last="Libersa">C. Libersa</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destee">A. Destee</name></author></analytic><series><title level="j">Journal of neural transmission (Vienna, Austria : 1996)</title><idno type="ISSN">0300-9564</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autonomic Nervous System Diseases (diagnosis)</term><term>Autonomic Nervous System Diseases (etiology)</term><term>Autonomic Nervous System Diseases (physiopathology)</term><term>Cardiovascular System (physiopathology)</term><term>Chronobiology Disorders (diagnosis)</term><term>Chronobiology Disorders (etiology)</term><term>Chronobiology Disorders (physiopathology)</term><term>Disease Progression</term><term>Female</term><term>Heart Rate (drug effects)</term><term>Heart Rate (physiology)</term><term>Humans</term><term>Hypokinesia (complications)</term><term>Hypokinesia (drug therapy)</term><term>Hypokinesia (physiopathology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Surveys and Questionnaires</term><term>Sympathetic Nervous System (physiopathology)</term><term>Up-Regulation (drug effects)</term><term>Up-Regulation (physiology)</term><term>Vagus Nerve (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hypokinesia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Chronobiology Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Heart Rate</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypokinesia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Chronobiology Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Heart Rate</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Cardiovascular System</term><term>Chronobiology Disorders</term><term>Hypokinesia</term><term>Parkinson Disease</term><term>Sympathetic Nervous System</term><term>Vagus Nerve</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Surveys and Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Heart rate variability (HRV) decrease in Parkinson's disease (PD) could only be a consequence of reduce motor activity besides of being a marker of cardiovascular dysautonomia. Under continuously recorded and standardised motor activity, we studied thirty patients compared to controls in 3 PD stages: group I: less than 2 year-evolution, slight impaired without L-dopa; group II: mildly impaired with L-dopa; group III: advanced PD with motor complications. No difference was observed between group I and controls. The diurnal low frequency power (LF) and the ratio of LF/high frequency (HF) power decreased in groups II and III. The nocturnal vagal indicators: HF power and pNN50 were decreased in group III. Those parameters were correlated with Off-drug-motor handicap, suggesting an evolutive HRV decrease with disease severity but not with On-drug-motor activity. The low LF despite the higher motor activity in group III, due to dyskinesias, suggested a defective cardiovascular up-regulation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12928836</PMID><DateCreated><Year>2003</Year><Month>08</Month><Day>20</Day></DateCreated><DateCompleted><Year>2004</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-9564</ISSN><JournalIssue CitedMedium="Print"><Volume>110</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neural transmission (Vienna, Austria : 1996)</Title><ISOAbbreviation>J Neural Transm (Vienna)</ISOAbbreviation></Journal><ArticleTitle>Heart rate variability and Parkinson's disease severity.</ArticleTitle><Pagination><MedlinePgn>997-1011</MedlinePgn></Pagination><Abstract><AbstractText>Heart rate variability (HRV) decrease in Parkinson's disease (PD) could only be a consequence of reduce motor activity besides of being a marker of cardiovascular dysautonomia. Under continuously recorded and standardised motor activity, we studied thirty patients compared to controls in 3 PD stages: group I: less than 2 year-evolution, slight impaired without L-dopa; group II: mildly impaired with L-dopa; group III: advanced PD with motor complications. No difference was observed between group I and controls. The diurnal low frequency power (LF) and the ratio of LF/high frequency (HF) power decreased in groups II and III. The nocturnal vagal indicators: HF power and pNN50 were decreased in group III. Those parameters were correlated with Off-drug-motor handicap, suggesting an evolutive HRV decrease with disease severity but not with On-drug-motor activity. The low LF despite the higher motor activity in group III, due to dyskinesias, suggested a defective cardiovascular up-regulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, EA 2683, CHU Lille, France. d-devos@chru-lille.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroumova</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vodougnon</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Guieu</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Libersa</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Destee</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm (Vienna)</MedlineTA><NlmUniqueID>9702341</NlmUniqueID><ISSNLinking>0300-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002319" MajorTopicYN="N">Cardiovascular System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="Y">Heart Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018476" MajorTopicYN="N">Hypokinesia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014630" MajorTopicYN="N">Vagus Nerve</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12928836</ArticleId><ArticleId IdType="doi">10.1007/s00702-003-0016-8</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001081 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001081 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:12928836
|texte= Heart rate variability and Parkinson's disease severity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12928836" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |